Page last updated: 2024-12-06

5-azacytosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-Azacytosine (5-AzaC) is a synthetic nucleoside analog that acts as a cytidine analog. It is a potent inhibitor of DNA methyltransferases (DNMTs), the enzymes responsible for DNA methylation. 5-AzaC is incorporated into DNA during replication, where it traps DNMTs, leading to their degradation and ultimately resulting in hypomethylation. Hypomethylation of DNA can activate gene expression, making it a promising agent for the treatment of various cancers and other diseases. 5-AzaC is used in the treatment of myelodysplastic syndromes (MDS), a group of hematologic malignancies. It has also been investigated for its potential therapeutic effects in other cancers, such as leukemia, lymphoma, and solid tumors. 5-AzaC is administered intravenously or orally. It can cause adverse effects, including myelosuppression, gastrointestinal disturbances, and hepatotoxicity. The mechanism of action of 5-AzaC is complex and involves multiple pathways, including the inhibition of DNMTs, activation of tumor suppressor genes, and induction of apoptosis. Research on 5-AzaC continues to explore its therapeutic potential in various diseases and its interactions with different cellular pathways.'

5-azacytosine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-azacytosine : A monoamino-1,3,5-triazine that is cytosine in which the aromatic CH at position 5 is replaced by a nitrogen. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID19956
CHEMBL ID1230389
CHEBI ID72474
SCHEMBL ID13863
SCHEMBL ID21169645
MeSH IDM0119044

Synonyms (64)

Synonym
AC-12915
5-aza-cytosine
chebi:72474 ,
CHEMBL1230389 ,
nsc54006
nsc51100
931-86-2
nsc-51100
nsc-54006
4-amino-1h-1,3,5-triazin-2-one
1,3,5-triazin-2(1h)-one, 4-amino-
5-azacytosine
nsc 51100
4-amino-1,3,5-triazin-2-one
einecs 213-242-9
s-triazin-2(1h)-one, 4-amino-
s-triazin-2-ol, 4-amino-
nsc 54006
4-amino-1,3,5-triazin-2(1h)-one
A-9450
2-amino-4-hydroxy-1,3,5-triazine
6-amino-1h-1,3,5-triazin-2-one
4-methoxy phencyclidine-d4 hydrochloride
5az ,
6-amino-1,3,5-triazin-2(1h)-one
AKOS002658026
2-amino-4-hydroxy-1,3,5-triazine; 4-amino-1,3,5-triazin-2-one
A844469
4040-10-2
bdbm50389508
4-amino-s-triazin-2(1h)-one
AKOS015919837
4-amino-1,3,5-triazin-2-ol
4-amino-2-hydroxy-1,3,5-triazine
2-hydroxy-4-aminotriazine
c5uw4ms7vr ,
unii-c5uw4ms7vr
5-azacytosine-15n4
FT-0601310
AKOS015854832
6-amino-1,2-dihydro-1,3,5-triazin-2-one
AM81319
SCHEMBL13863
azacytosine
mfcd00006033
SY030603
4-amino-1,3,5-triazin-2(1h)-one #
2-amino-4-hydroxy-sym-triazine
2-amino-4-hydroxy-s-triazine
5-aza cytosine
DTXSID80239275
1118000-83-1
CS-0008471
Z1962222528
BCP22914
Q27139948
3,4-dihydro-2h-benzo[1,4]oxazine-6-carboxylicacid
5-azacytosine (4-amino-1,3,5-triazin-2(1h)-one)
AS-10943
SCHEMBL21169645
A51119
mfcd00051007
1216950-61-6
EN300-136571
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monoamino-1,3,5-triazine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
atrazine degradation I (aerobic)413
superpathway of atrazine degradation718

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
CPG DNA methylaseSpiroplasma monobiaeKi5,500.00000.02800.12900.2300AID675175
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID675175Competitive inhibition of Spiroplasma sp. MQ1 SssI methyltransferase using pUC18 as substrate measured for 10 mins by Dixon plot analysis2012European journal of medicinal chemistry, Sep, Volume: 55New cytosine derivatives as inhibitors of DNA methylation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (25.64)18.7374
1990's4 (10.26)18.2507
2000's12 (30.77)29.6817
2010's12 (30.77)24.3611
2020's1 (2.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.57 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.44%)5.53%
Reviews2 (4.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other38 (92.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]